JP2020511425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511425A5 JP2020511425A5 JP2019539809A JP2019539809A JP2020511425A5 JP 2020511425 A5 JP2020511425 A5 JP 2020511425A5 JP 2019539809 A JP2019539809 A JP 2019539809A JP 2019539809 A JP2019539809 A JP 2019539809A JP 2020511425 A5 JP2020511425 A5 JP 2020511425A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide according
- use according
- apoc
- peptide
- hypertriglyceridemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 204
- 150000001413 amino acids Chemical class 0.000 claims description 40
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 32
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 14
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 238000012300 Sequence Analysis Methods 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 101150062900 lpl gene Proteins 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 description 55
- 235000014113 dietary fatty acids Nutrition 0.000 description 52
- 229930195729 fatty acid Natural products 0.000 description 52
- 239000000194 fatty acid Substances 0.000 description 52
- 150000004665 fatty acids Chemical class 0.000 description 52
- 238000000034 method Methods 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 16
- 239000004472 Lysine Substances 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- 235000003704 aspartic acid Nutrition 0.000 description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 8
- 238000007385 chemical modification Methods 0.000 description 8
- 235000013922 glutamic acid Nutrition 0.000 description 8
- 239000004220 glutamic acid Substances 0.000 description 8
- 102000043296 Lipoprotein lipases Human genes 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 239000004475 Arginine Chemical group 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 5
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical group CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 101000959921 Homo sapiens Apolipoprotein C-II Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100171A JP2023116739A (ja) | 2017-01-19 | 2023-06-19 | Ａｐｏｃ－ｉｉ模倣ペプチド |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448358P | 2017-01-19 | 2017-01-19 | |
| US62/448,358 | 2017-01-19 | ||
| US201762476535P | 2017-03-24 | 2017-03-24 | |
| US201762476531P | 2017-03-24 | 2017-03-24 | |
| US62/476,531 | 2017-03-24 | ||
| US62/476,535 | 2017-03-24 | ||
| PCT/US2018/014532 WO2018136803A1 (en) | 2017-01-19 | 2018-01-19 | Apoc-ii mimetic peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100171A Division JP2023116739A (ja) | 2017-01-19 | 2023-06-19 | Ａｐｏｃ－ｉｉ模倣ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511425A JP2020511425A (ja) | 2020-04-16 |
| JP2020511425A5 true JP2020511425A5 (https=) | 2021-02-04 |
| JP7353973B2 JP7353973B2 (ja) | 2023-10-02 |
Family
ID=62908746
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539809A Active JP7353973B2 (ja) | 2017-01-19 | 2018-01-19 | Ａｐｏｃ－ｉｉ模倣ペプチド |
| JP2023100171A Pending JP2023116739A (ja) | 2017-01-19 | 2023-06-19 | Ａｐｏｃ－ｉｉ模倣ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100171A Pending JP2023116739A (ja) | 2017-01-19 | 2023-06-19 | Ａｐｏｃ－ｉｉ模倣ペプチド |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11136372B2 (https=) |
| EP (1) | EP3571216A4 (https=) |
| JP (2) | JP7353973B2 (https=) |
| KR (1) | KR102700862B1 (https=) |
| CN (1) | CN110831957B (https=) |
| AU (1) | AU2018210404B2 (https=) |
| BR (1) | BR112019014707A2 (https=) |
| CA (1) | CA3050106A1 (https=) |
| IL (2) | IL268093B2 (https=) |
| MX (1) | MX2019008529A (https=) |
| NZ (1) | NZ755599A (https=) |
| SG (2) | SG10201911974UA (https=) |
| TW (2) | TW202130652A (https=) |
| WO (1) | WO2018136803A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202130652A (zh) | 2017-01-19 | 2021-08-16 | 美國衛生與公眾服務部 | Apoc-ii擬肽 |
| CN117580857A (zh) * | 2021-06-23 | 2024-02-20 | 美国政府(由卫生和人类服务部的部长所代表) | Apoc-ii短模拟肽及使用方法 |
| IL316418A (en) * | 2022-05-05 | 2024-12-01 | Us Health | Short apolipoprotein E mimetic peptides and methods of use |
| WO2024036145A1 (en) * | 2022-08-07 | 2024-02-15 | Protean Bio, Inc. | Peptides for beta-cell survival and insulin production |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US6156727A (en) * | 1996-09-05 | 2000-12-05 | Uab Research Foundation | Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis |
| PL372925A1 (en) * | 2001-09-28 | 2005-08-08 | Esperion Therapeutics Inc. | Prevention and treatment of restenosis by local administration of drug |
| US7220576B2 (en) * | 2002-01-07 | 2007-05-22 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| AU2004207444B2 (en) * | 2003-01-17 | 2008-07-31 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| CA2549529A1 (en) * | 2003-12-15 | 2005-06-30 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
| CN100567270C (zh) * | 2004-02-19 | 2009-12-09 | 万有制药株式会社 | 磺酰胺衍生物 |
| KR101185609B1 (ko) * | 2004-07-16 | 2012-09-24 | 트러스티즈 오브 터프츠 칼리지 | 아포리포단백질 ａ１ 미메틱 및 이의 용도 |
| AU2006263332B2 (en) * | 2005-06-29 | 2012-02-23 | Hadasit Medical Research Services & Development Ltd. | Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes |
| WO2008039843A2 (en) * | 2006-09-26 | 2008-04-03 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
| WO2009097584A1 (en) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
| US8936787B2 (en) * | 2008-04-15 | 2015-01-20 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Peptides promoting lipid efflux |
| US20120270771A1 (en) | 2009-09-30 | 2012-10-25 | Snu R&Db Foundation | Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same |
| ES2859559T3 (es) * | 2012-11-06 | 2021-10-04 | Les Hopitaux Univ De Geneve | Péptidos miméticos |
| TW202130652A (zh) | 2017-01-19 | 2021-08-16 | 美國衛生與公眾服務部 | Apoc-ii擬肽 |
| EA201991491A1 (ru) | 2017-03-24 | 2019-12-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис | Миметические пептиды apoc-ii |
-
2018
- 2018-01-19 TW TW109138699A patent/TW202130652A/zh unknown
- 2018-01-19 TW TW107102123A patent/TWI788323B/zh active
- 2018-01-19 SG SG10201911974UA patent/SG10201911974UA/en unknown
- 2018-01-19 MX MX2019008529A patent/MX2019008529A/es unknown
- 2018-01-19 KR KR1020197024024A patent/KR102700862B1/ko active Active
- 2018-01-19 IL IL268093A patent/IL268093B2/en unknown
- 2018-01-19 US US16/479,183 patent/US11136372B2/en active Active
- 2018-01-19 AU AU2018210404A patent/AU2018210404B2/en active Active
- 2018-01-19 CN CN201880019604.7A patent/CN110831957B/zh active Active
- 2018-01-19 NZ NZ755599A patent/NZ755599A/en unknown
- 2018-01-19 CA CA3050106A patent/CA3050106A1/en active Pending
- 2018-01-19 JP JP2019539809A patent/JP7353973B2/ja active Active
- 2018-01-19 SG SG11201906422VA patent/SG11201906422VA/en unknown
- 2018-01-19 WO PCT/US2018/014532 patent/WO2018136803A1/en not_active Ceased
- 2018-01-19 BR BR112019014707A patent/BR112019014707A2/pt unknown
- 2018-01-19 EP EP18742118.5A patent/EP3571216A4/en active Pending
-
2020
- 2020-12-29 IL IL279831A patent/IL279831A/en unknown
-
2021
- 2021-03-09 US US17/195,766 patent/US11827690B2/en active Active
-
2023
- 2023-06-19 JP JP2023100171A patent/JP2023116739A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7497381B2 (ja) | Ｆｇｆ２１変異体 | |
| JP7309606B2 (ja) | 活性比が最適化されたｆｇｆ２１化合物／ｇｌｐ－１ｒアゴニスト組合せ物 | |
| JP6227629B2 (ja) | ヒトアミリン類似体 | |
| CN103596972B (zh) | 多肽 | |
| JP2024105462A (ja) | 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ－１ｒアゴニストの組合せ | |
| JP5485876B2 (ja) | 代謝疾患の治療における治療剤としての非アシル化グレリン | |
| DK2344519T3 (en) | C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1) | |
| DK2389388T3 (en) | TREATMENT FOR Obesity | |
| JP2020511425A5 (https=) | ||
| EP3570875B1 (en) | Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use | |
| JP2013505221A (ja) | 長時間作用性ｙ２受容体アゴニスト | |
| CN106661096A (zh) | 新的艾塞那肽类似物及其用途 | |
| WO2022177878A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| RU2010120571A (ru) | Тимус-специфический белок | |
| WO2015180634A1 (zh) | 用于治疗2型糖尿病的长效肠激素多肽类似物及应用 | |
| CN119654159A (zh) | 胰高血糖素样肽-1受体拮抗剂 | |
| CN109195983B (zh) | 胰岛新生多肽和类似物的缀合物及其方法 | |
| JP2024532882A5 (https=) | ||
| HK40034568A (en) | Fgf21 variants | |
| WO2014014816A2 (en) | Methods of treating glucose metabolism disorders |